An Gong Niuhuang Wan Promotes the Postoperative Neurological Function Recovery of Patients With Traumatic Brain Injury
Condition(s) studied
Investigational drug(s) / intervention(s)
Jianmin Daopeng Angong Niuhuang Wan: An Gong Niu Huang Wan comes from JianMin Dapeng.
Tongrentang Angong Niuhuang Wan: Angong Niuhuang Wan comes from Tongrentang.
Study summary
Clinical Challenges and Severity of Traumatic Brain Injury: Traumatic brain injury, as a common neurosurgical disease, poses a significant threat to patients' life safety and quality of life.The promotion of in vitro cultivated cow bile in the treatment of post-traumatic brain injury is expected to provide a more economical and effective treatment option for the recovery of consciousness and cognitive functions of TBI patients. Compared with traditional An Gong Niu Huang Wan, Jian Min Da Peng's An Gong Niu Huang Wan (containing in vitro cultivated cow bile) can not only reduce treatment costs, but also improve the stability and consistency of the quality of the drug. The above clinical research can provide scientific basis for including it in relevant treatment guidelines.
Eligibility
Primary outcome measure(s)
- The changes in GCS scores before and after treatment 2 week — 2 week
We compared the improvement effects of oral administration of Jianmin Dapeng An Gong Niu Huang Wan (containing in vitro cultivated rhinoceros horn) and Tong Ren Tang An Gong Niu Huang Wan (containing natural rhinoceros horn) on the recovery of neurological function in patients with brain trauma after surgery (calculation method: compare the changes in GCS before and after treatment of the two groups, the improvement effect of neurological function = final GCS test score - GCS test score before treatment)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Tongji hospital | Wuhan | Hubei | Recruiting |
More Huaqiu Zhang trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07074938 on ClinicalTrials.gov ↗ ← All trials in China